TITLE

Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside?

AUTHOR(S)
Sancho-Bru, P.; Najimi, M.; Caruso, M.; Pauwelyn, K.; Cantz, T.; Forbes, S.; Roskams, T.; Ott, M.; Gehling, U.; Sokal, E.; Verfaillie, C. M.; Muraca, M.
PUB. DATE
April 2009
SOURCE
Gut;Apr2009, Vol. 58 Issue 4, p594
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
There has been recent progress in the isolation and characterisation of stem/progenitor cells that may differentiate towards the hepatic lineage. This has raised expectations that therapy of genetic or acquired liver disease might be possible by transplanting stem/progenitor cells or their liver-committed progeny. However, it is currently impossible to determine from the many documented studies which of the stem/progenitor cell populations are the best for therapy of a given disease. This is largely because of the great variability in methods used to characterise cells and their differentiation ability, variability in transplantation models and inconsistent methods to determine the effect of cell grafting in vivo. This manuscript represents a first proposal, created by a group of investigators ranging from basic biologists to clinical hepatologists. It aims to define standardised methods to assess stem/progenitor cells or their hepatic lineage-committed progeny that could be used for cell therapy in liver disease. Furthermore standardisation is suggested both for preclinical animal models to evaluate the ability of such cells to repopulate the liver functionally, and for the ongoing clinical trials using mature hepatocytes. Only when these measures have been put in place will the promise of stem/progenitor-derived hepatocyte-based therapies become reality.
ACCESSION #
45646944

 

Related Articles

  • Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells. Nowak, Bernd; Weber, Christian; Schober, Andreas; Zeiffer, Ute; Liehn, Elisa A.; von Hundelshausen, Philipp; Reinartz, Patrick; Schaefer, Wolfgang M.; Buell, Ulrich // European Journal of Nuclear Medicine & Molecular Imaging;May2007, Vol. 34 Issue 5, p715 

    Cell-based therapy by transplantation of progenitor cells has emerged as a promising development for organ repair, but non-invasive imaging approaches are required to monitor the fate of transplanted cells. Radioactive labelling with 111In-oxine has been used in preclinical trials. This study...

  • Non-myeloablative stem cell transplantation for autoimmune diseases. Burt, Richard; Verda, Larissa; Oyama, Yu; Statkute, Laisvyde; Slavin, Shimon // Springer Seminars in Immunopathology;Sep2004, Vol. 26 Issue 1/2, p57 

    Treatment of life-threatening autoimmune diseases in animal models with induced or spontaneous autoimmune diseases can be accomplished by a 2-step procedure involving elimination of self-reactive lymphocytes with an immune ablative conditioning regimen followed by infusion of autologous or...

  • MolMed's Cell Therapy in Pivotal European Trial; U.S. Study Next. Boggs, Jennifer // BioWorld Today;6/9/2008, Vol. 19 Issue 111, p1 

    The article offers information on a clinical trial being conducted by MolMed SpA of Milan, Italy for its TK cell therapy in leukemia patients. The company aims to increase the chances of survival in leukemia patients undergoing stem cell transplantation with partially incompatible family donors....

  • Chemokine and lymph node homing receptor expression on pDC vary by graft source. Hosoba, Sakura; Harris, Wayne AC; Lin, Kaifeng L; Waller, Edmund K // OncoImmunology;Oct2014, Vol. 3 Issue 10, pN.PAG 

    A randomized clinical trial of BM vs. blood stem cell transplants from unrelated donors showed that more plasmacytoid dendritic cells (pDCs) in BM grafts was associated with better post-transplant survival. Here, we describe differences in homing-receptor expression on pDC to explain observed...

  • A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Rowley, S D; Feng, Z; Chen, L; Holmberg, L; Heimfeld, S; MacLeod, B; Bensinger, W I // Bone Marrow Transplantation;Jun2003, Vol. 31 Issue 11, p1043 

    Summary:Hematopoietic stem cells intended for autologous transplantation are usually cryopreserved in solutions containing 10% dimethylsulfoxide (DMSO, v/v) or 5% DMSO in combination with 6% hydroxyethylstarch (HES, w/v). We performed a single-blinded, randomized study comparing these...

  • Allogeneic stem cell transplantation for treatment of immunodeficiency. Friedrich, Wilhelm; Müller, Susanna // Springer Seminars in Immunopathology;Sep2004, Vol. 26 Issue 1/2, p109 

    Primary immunodeficiencies constitute a group of highly complex congenital disorders commonly characterized by an extremely poor prognosis. Allogeneic hematopoietic stem cell transplantation has the potential to establish a permanently functioning immune system and represents a curative approach...

  • Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Dignan, F.; Gujral, D.; Ethell, M.; Evans, S.; Treleaven, J.; Morgan, G.; Potter, M. // Bone Marrow Transplantation;Jul2007, Vol. 40 Issue 1, p79 

    Veno-occlusive disease (VOD) is a common and high-risk complication of allogeneic stem cell transplantation (SCT). Defibrotide has recently been used successfully to treat the disorder. We report on 58 patients who received defibrotide prophylaxis without concurrent heparin. No patients...

  • Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Pulanic, D.; Lozier, J. N.; Pavletic, S. Z. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p393 

    Chronic graft versus host disease (cGVHD) is a major and frequent late complication in allogeneic stem cell transplantation recipients. Although thrombocytopenia in cGVHD patients is among the most consistent and strongest predictors of poor survival across many cGVHD studies, such correlation...

  • Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. Kakinuma, Sei; Nakauchi, Hiromitsu; Watanabe, Mamoru // Journal of Gastroenterology;2009, Vol. 44 Issue 3, p167 

    Allogeneic liver transplantation is still the only effective treatment available to patients with liver failure. However, because there is a serious shortage of liver donors, an alternative therapeutic approach is needed. Transplantation of mature hepatocytes has been evaluated in clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics